Table 3.
Demographics of participant accrual, by protocol
| Organ Site | Study ID |
Brief Description | Protocol Design | Protocol Eligibility | Protocol Features | |||
|---|---|---|---|---|---|---|---|---|
| Randomized | Not Randomized |
Early stage disease |
Regional or locally advanced disease |
Investigational systemic therapy + Surgery |
Primary surgery study |
|||
| Breast | Z0010 | Prospective study of sentinel node and bone marrow micrometastases | √ | √ | √ | |||
| Breast | Z0010 | Randomized trial of axillary node dissection | √ | √ | √ | |||
| Breast | Z1031 | Randomized phase III trial of neoadjuvant aromatase inhibitors | √ | √ | √ | |||
| Sarcoma | Z9000 | Phase II study of adjuvant ST1571 therapy | √ | √ | √ | |||
| Sarcoma | Z9001 | Phase III randomized double-blind study of adjuvant ST1571 versus placebo | √ | √ | √ | |||
| Thoracic | Z0030 | Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy | √ | √ | √ | |||
| Thoracic | Z0040 | Prospective study of prognostic significance of occult metastases | √ | √ | √ | |||
| Thoracic | Z0050 | Utility of positron emission tomography (PET) in NSCLC | √ | √ | √ | |||
| Thoracic | Z0060 | Utility of positron emission tomography (PET) in esophageal CA | √ | √ | √ | |||
| Thoracic | Z4031 | Use of proteomic analysis of serum samples in NSCLC | √ | √ | √ | |||